• Founded: 2020
  • Location: South SF, CA
  • Employee range: 0 - 0
  • Clinical stage: Clin1
  • Therapy area: Systemic amyloidosis
  • Drug types: RAR, NEU
  • Lead product: AT-02
  • Product link:
  • Funding: $116M B Sep 2021; $25M A Sep 2020

job board

Short description:

Amyloidosis Treatments

Drug notes:

AT-03 Clin0 systemic amyloidosis; AT-04 Clin0 systemic amyloidosis, neurodegenerative/CNS disorders; AT-06 RD/Clin0 systemic amyloidosis

Long description:

Attralus is developing methods to diagnose and treat patients with systemic amyloid diseases. There are currently no treatments to remove toxic amyloid from patients with systemic amyloidosis. To address this unmet need, Attralus is pioneering pan-amyloid removal (PAR) therapeutics that are capable of diagnosing and treating all types of systemic amyloidosis. To develop novel PAR therapeutics Attralus is using their proprietary amyloid binding peptide that has a unique structure providing highly specific binding to multiple accessible sites on disease-causing amyloid deposits. Attralus also uses modular biologics design to combine their peptides with a variety of different biomolecules for multiple downstream applications from imaging agents to amyloid removal.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy